Get started
Author

Marine Oriel

Observed name: M. Oriel
ORCID: 0009-0005-3296-575X
Observed ORCID: 0009-0005-3296-575X
OpenAlex ID: A5063860959
Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate of Patients With Metastatic Renal Cell Carcinomas
2024 · F. Moinard-Butot, M. Oriel, et al. · Clinical Genitourinary Cancer · 5
PDF
Effect of treatment of residual disease after immunotherapy-based combinations on complete response rate in metastatic renal cell carcinoma.
2023 · Fabien Moinard-Butot, Marine Oriel, et al. · Journal of Clinical Oncology · 2
Efficacy and Safety of Weekly P-C-CTX Induction in LA-HNSCC Patients Ineligible for Upfront Cisplatin-Based Chemoradiotherapy
2026 · Marine Oriel, Helene Carinato, et al. · Radiotherapy and Oncology
IMMUN-NEO-ORL: Evaluation of the Efficacy of Neoadjuvant Immunochemotherapy in Patients with Locally Advanced HNSCC Unresectable
2026 · Marine Oriel, Hélène Carinato, et al. · Radiotherapy and Oncology
Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).
2024 · Christian Borel, Hélène Carinato, et al. · Journal of Clinical Oncology
Works count: 5
Citation count: 7
H-index: 2
I10-index:
Year
Topic
Type